Estradiol sulfate (E2S), or 17β-estradiol 3-sulfate,[1] is a natural, endogenous steroid and an estrogen ester.[2] E2S itself is biologically inactive,[3] but it can be converted by steroid sulfatase (also called estrogen sulfatase) into estradiol, which is a potent estrogen.[2][4][5] Simultaneously, estrogen sulfotransferases convert estradiol to E2S, resulting in an equilibrium between the two steroids in various tissues.[2][5]Estrone and E2S are the two immediate metabolic sources of estradiol.[6] E2S can also be metabolized into estrone sulfate (E1S), which in turn can be converted into estrone and estradiol.[7] Circulating concentrations of E2S are much lower than those of E1S.[1] High concentrations of E2S are present in breast tissue, and E2S has been implicated in the biology of breast cancer via serving as an active reservoir of estradiol.[2][4]
As the sodium saltsodium estradiol sulfate, E2S is present as a minor constituent (0.9%) of conjugated equine estrogens (CEEs), or Premarin.[8] It effectively functions as a prodrug to estradiol in this preparation, similarly to E1S. E2S is also formed as a metabolite of estradiol, as well as of estrone and E1S.[9][10] Aside from its presence in CEEs, E2S is not available as a commercial pharmaceutical drug.[11]
E2S shows about 10,000-fold lower potency in activating the estrogen receptors relative to estradiol in vitro.[12] It is 10-fold less potent than estrone sulfate orally in terms of in vivouterotrophic effect in rats.[13] Estrogen sulfates like estradiol sulfate or estrone sulfate are about twice as potent as the corresponding free estrogens in terms of estrogenic effect when given orally to rodents.[14] This in part led to the introduction of conjugated estrogens (Premarin), which are primarily estrone sulfate, in 1941.[14]
Estradiol levels are about 1.5- to 4-fold higher than E2S levels in women. This is in contrast to E1S, the levels of which are about 10 to 15times higher than those of estrone.[17]
E2S at an oral dosage of 5mg/day in women resulted in inhibition of ovulation in 89% of cycles (47 of 53).[18]
Wang, Li-Quan; James, Margaret O. (2005). "Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate". The Journal of Steroid Biochemistry and Molecular Biology. 96 (5): 367–374. doi:10.1016/j.jsbmb.2005.05.002. ISSN0960-0760. PMID16011896. S2CID24671971.
Bhavnani BR (November 1988). "The saga of the ring B unsaturated equine estrogens". Endocr. Rev. 9 (4): 396–416. doi:10.1210/edrv-9-4-396. PMID3065072.
Herr, F.; Revesz, C.; Manson, A. J.; Jewell, J. B. (1970). "Biological Properties of Estrogen Sulfates". Chemical and Biological Aspects of Steroid Conjugation. pp.368–408. doi:10.1007/978-3-642-95177-0_8 (inactive 2024-03-25). ISBN978-3-642-95179-4.{{cite book}}: CS1 maint: DOI inactive as of March 2024 (link)
Singh D, Pandey RS (1996). "Glutathione-S-transferase in rat ovary: its changes during estrous cycle and increase in its activity by estradiol-17 beta". Indian J. Exp. Biol. 34 (11): 1158–60. PMID9055636.
Gual C, Becerra C, Rice-Wray E, Goldzieher JW (February 1967). "Inhibition of ovulation by estrogens". Am J Obstet Gynecol. 97 (4): 443–7. doi:10.1016/0002-9378(67)90555-8. PMID4163201.
Share this article:
This article uses material from the Wikipedia article Estradiol_sulfate, and is written by contributors.
Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.